InflaRx NV

InflaRx NV’s Phase 2a INF904 results due 10 Nov 2025 could redefine its pipeline, valuation, and investor sentiment, sparking a potential rally or shift to sell.

InflaRx NV, a clinical-stage biopharmaceutical company, is advancing the development of monoclonal antibody therapies to treat inflammatory diseases, with a robust pipeline of investigational drugs and a growing presence in the global biotechnology …

InflaRx NV, a clinical-stage biopharmaceutical company, is making strides in the biotechnology industry by developing innovative monoclonal antibody therapies for inflammatory diseases, with a focus on patient care and strategic growth.